New trial: can targeted radiation boost survival in patients with up to 10 metastases?

NCT ID NCT05717166

Recruiting now Disease control Sponsor: David Palma Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase III trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard treatment (chemotherapy, hormone therapy, or palliative radiation) improves survival in adults with 1 to 10 metastatic tumors and an active primary cancer. About 180 participants will be randomly assigned to standard care alone or standard care plus SABR. The study aims to see if this approach extends life and preserves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Stereotactic ablative radiotherapy (SABR)
What this could lead to: If successful, this could show that adding precise, high-dose radiation to standard treatment helps people with limited metastatic cancer live longer and maintain quality of life.
What could go wrong: This is a relatively early phase III trial with 180 participants, so results may not apply to all cancer types. SABR can cause side effects like fatigue or damage to nearby organs, and it may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm metastatic neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC TUMOR

Contacts and locations

Locations

BC Cancer - Centre for the North
NOT_YET_RECRUITING

Prince George, British Columbia, V2M 7E9, Canada
BC Cancer - Vancouver
RECRUITING

Vancouver, British Columbia, V5Z 4C2, Canada
Centre Hospitalier de l'Université de Montréal-CHUM
RECRUITING

Montreal, Quebec, H2X 0C1, Canada
London Regional Cancer Program of the Lawson Health Research Institute
RECRUITING

London, Ontario, N6A 5W9, Canada
Universitätsspital Zürich
RECRUITING

Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.